Document is current
Any future updates will be listed below
-
Authors
Chandasana, Hardik https://orcid.org/0000-0002-1289-0800
van Dijkman, Sven C.
Mehta, Rashmi
Bush, Mark
Rabie, Helena
Flynn, Patricia
Cressey, Tim R.
Acosta, Edward P.
Brooks, Kristina M.
,
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 13 June 2024
First Online: 4 July 2024
Declarations
:
: Hardik Chandasana, Sven van Dijkman, and Rashmi Mehta are employee of GSK and owns stock in GSK. Mark Bush is an employee of ViiV Healthcare and own stock in GSK. Kristina M Brooks received consulting fees from ViiV Healthcare. Helena Rabie, Patricia Flynn, Tim Cressey, and Edward Acosta have nothing to declare.
: The IMPAACT 2019 study (ClinicalTrials gov identifier NCT03760458) was designed in accordance with the International Council for Harmonization, Good Clinical Practice guidelines [], and applicable country-specific requirements and abided by the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all the participants before screening. Institutional review boards and national authorities reviewed and approved the trial protocol, amendments, and informed consent forms.
